Firm says new cell line will facilitate measurement of endogenous receptors.

Axxam and Lonza signed a license agreement that will allow the latter to include Axxam’s Photina®, iPhotina®, and Clytin® photoproteins as calcium biosensors in its range of Clonetics® primary cells.

The Photina technology is a Ca2+-activated photoprotein optimized for the generation of precise Ca2+ mobilization assays for high-throughput screening, Axxam claims. The product  combines part of the obelin photoprotein with a part of clytin. iPhotina has been developed as an improved version of Photina that retains the same mechanism of action and characteristics but with an increased light release.

Lonza’s Clonetics Primary Sensors have been developed to help researchers measure drug targets in a biologically relevant environment, the firm states. The sensor is added to the cell by Lonza using the Amaxa Nucleofector® technology. The substrate is then added before the cells are frozen, ready for use.

“Our newly introduced Clonetics Primary Sensors range of products allows customers to access their primary cells of choice and measure endogenous receptor activity using the same technologies and protocols that they are used to using with overexpressing cell lines,” remarks Leon de Bruin, senior product manager for Lonza’s drug discovery marketing group.

Previous articleGSK and Prosensa Expand Ongoing Exon-Skipping DMD Therapeutics Alliance
Next articleSantaris Receives Minority miRagen Stake through Cardiovascular Therapeutics Deal